Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exelixis Slashes Staff Again, Focuses All Internal Development on XL184

This article was originally published in The Pink Sheet Daily

Executive Summary

As many as 65% of the oncology biotech's employees could be shown the door as the company ceases research on all but one drug candidate.

You may also be interested in...



Panel: Oncology Business Models Determined By Capital And Culture

Panelists with a variety of strategic motives met to discuss the pros and cons of business models at the Cancer Progress Meeting in New York City. The group represented both new and old firms, including some that perform research and some that license drugs.

Solution Development: A Model For Structuring Biotechs And Developing Better Drugs

The biopharma industry must think differently about funding high-risk/reward development of drug candidates against novel targets. Multiplexing Phase II proof-of-concept trials can light a path toward lower-risk pivotal studies and provide a model for building biotechs to deliver what patients, providers, payors, and investors all want: solutions.

Oncology Start-up Cyterix Pharmaceuticals Launches With $9.2MM From VCs

Two venture firms bet on the Scottish university spin-out, now based California, as it develops pro-drugs activated by a specific enzyme family.

Related Content

Topics

UsernamePublicRestriction

Register

PS071555

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel